Breaking News
Investing Pro 0
Free Webinar - Webinar: Simplify Options Trading | Thursday, September 28, 2023 | 08:00PM EDT Enroll Now
Close

Amgen Inc (AMGN)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
4,630.11 0.00    0.00%
26/09 - Closed. Currency in MXN ( Disclaimer )
Type:  Equity
Market:  Mexico
ISIN:  US0311621009 
S/N:  031162100
  • Volume: 0
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 4,630.11 - 4,630.11
Amgen 4,630.11 0.00 0.00%

Amgen Inc Company Profile

 
Get an in-depth profile of Amgen Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

25200

Equity Type

ORD

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company’s products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Contact Information

Address One Amgen Center Drive
Thousand Oaks, 91320-1799
United States
Phone 805 447 1000
Fax 805 447 1010

Top Executives

Name Age Since Title
Robert A. Bradway 58 2007 Chairman, CEO & President
R. Sanders Williams 74 2014 Independent Director
Maria T. Abreu - 2022 Member of Scientific Advisory Board of Inflammation
Ronald D. Sugar 74 2010 Independent Director
Greg C. Garland 66 2013 Independent Director
Charles M. Holley 66 2017 Independent Director
Robert A. Eckert 69 2012 Lead Independent Director
Tyler E. Jacks 62 2012 Independent Director
Ellen J. Kullman 67 2016 Independent Director
S. Omar Ishrak 67 2021 Independent Director
Brian J. Druker 67 2018 Independent Director
Amy E. Miles 56 2020 Independent Director
Wanda M. Austin 69 2017 Independent Director
Michael V. Drake - 2022 Independent Director
Alexander Rudensky - 2022 Member of Scientific Advisory Board of Inflammation
Emma Guttman-Yassky - 2022 Member of Scientific Advisory Board of Inflammation
Meilan Han - 2022 Member of Scientific Advisory Board of Inflammation
John Kuriyan - - Member of Scientific Advisory Board of Research Trends & Emerging Technologies
Diane J. Mathis - - Member of Scientific Advisory Board of Inflammation
Alexander Marson - 2022 Member of Scientific Advisory Board of Inflammation
Arlene Sharpe - 2022 Member of Scientific Advisory Board of Inflammation
George Georgiou 64 2023 Member of Scientific Advisory Board of Research Trends & Emerging Technologies
Richard O. Hynes - - Member of Scientific Advisory Board of Research Trends & Emerging Technologies
Dean Sheppard - 2022 Member of Scientific Advisory Board of Inflammation
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

AMGN Comments

Write your thoughts about Amgen Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Denys Bondarenko
Denys Bondarenko Sep 21, 2023 3:07PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
November - 297$
Denys Bondarenko
Denys Bondarenko Sep 21, 2023 3:06PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
If you didnt buy today at the drop then you missed out big time
Szigi80
Szigi80 Jun 13, 2023 3:41PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Time for the bulls
Alp Gunaydin
Alp Gunaydin Jun 02, 2023 5:59PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Great valuation for entry
Neku Daniel okpako
Neku Daniel okpako Apr 18, 2023 9:41AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Write your thoughts about Amgen
Crim Jamer
Crim Jamer Apr 18, 2023 9:41AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Can go up, down or trading sideways
Vahid Golzari
Vahid Golzari Jun 29, 2022 1:13PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
BTC
فواز ساجت
فواز ساجت Apr 02, 2022 12:57PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
gvx
جمال ناصر
جمال ناصر Mar 31, 2022 12:44PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
psps
PS PS
PS PS Mar 28, 2022 5:28PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
$BCRX
amir asgari
amir asgari Feb 08, 2022 7:27AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
amir asgari
amir asgari Feb 08, 2022 7:27AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
hi dear
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email